EDAP to Present at the Jefferies Global Healthcare ConferenceAUSTIN, Texas, May 27, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to deliver a presentation and host 1x1 investor meetings at the Jefferies Global Healthcare Conference, which is being held June 3-5, 2025, in New York City.
EDAP to Announce First Quarter 2025 Financial Results on May 15, 2025Company to host conference call and webcast on Thursday, May 15th at 8:30am EDT
EDAP Announces Positive Results from the FARP Randomized Controlled Trial Presented at the American Urological Association (AUA) Annual MeetingAUSTIN, Texas, April 29, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced the positive final results of the Focal Ablation Versus Radical Prostatectomy (FARP) Study, the first randomized controlled trial completed comparing ultrasound energy-based focal ablation versus Robotic Prostatectomy. The study achieved its primary endpoint and demonstrated that the rate of treatment failure in the Focal Ablation (FA) group is non-inferior to that in the Radical Prostatectomy (RP) group at the final 36-month follow-up.
EDAP To Launch New Focal One® i Robotic HIFU system at the Upcoming 120th American Urological Association (AUA) Annual MeetingAUSTIN, Texas, April 24, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced the launch of the new Focal One i system at the upcoming 120th American Urological Association (AUA) Annual Meeting being held in Las Vegas, Nevada from April 26-29, 2025.
EDAP Announces Significant Presence of Focal One® at the Upcoming 120th American Urological Association (AUA) Annual MeetingAUSTIN, Texas, April 22, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that Focal One will have its largest presence ever at the upcoming 120th American Urological Association (AUA) Annual Meeting.
Cortechs.ai and EDAP Announce World’s First OnQ™ Prostate-Assisted Focal One® Robotic HIFU Procedure at UCSF Prostate Cancer CenterSan Diego, CA and Austin, Texas, February 6, 2025 - Cortechs.ai, an emerging leader in novel imaging solutions for prostate cancer care, and EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced the successful completion of the world’s first OnQ Prostate-assisted Focal One® Robotic HIFU procedure at the University of California, San Francisco (UCSF) Prostate Center. This milestone marks the first clinical application of OnQ Prostate’s patented RSI technology to guide focal therapy, demonstrating how advanced MR-imaging can improve lesion localization and targeting for urologists performing focal therapy.
EDAP Announces First Pancreatic Cancer Patient Treated with Proprietary HIFU TechnologyAUSTIN, Texas, January 8, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that the first patient has been treated in a phase I/II PULS Trial sponsored by the Centre Léon Bérard, Lyon, France, evaluating proprietary High Intensity Focused Ultrasound (HIFU) technology for the treatment of pancreatic tumors.
EDAP to Announce Third Quarter 2024 Financial Results on November 7, 2024Company to host conference call and webcast on Thursday, November 7th at 8:30am EDT
